Antimicrobial antagonists against food pathogens; a bacteriocin perspective by O'Connor, Paula M. et al.
 TITLE: Antimicrobial antagonists against food pathogens; a bacteriocin perspective 
AUTHORS: Paula M. O’Connor, R. Paul Ross, Colin Hill, Paul D. Cotter 
This article is provided by the author(s) and Teagasc T-Stór in accordance with publisher policies. 
Please cite the published version. 
The correct citation is available in the T-Stór record for this article. 
NOTICE: This is the author’s version of a work that was accepted for publication in Current 
Opinion in Food Science. Changes resulting from the publishing process, such as peer review, 
editing, corrections, structural formatting, and other quality control mechanisms may not be 
reflected in this document. Changes may have been made to this work since it was submitted for 
publication. A definitive version was subsequently published in Current Opinion in Food Science, 
Volume 2, April 2015, Pages 51–57. doi :10.1016/j.cofs.2015.01.004 
This item is made available to you under the Creative Commons Attribution-Non commercial-No 
Derivatives 3.0 License. 
 
Antimicrobial antagonists against food pathogens; a bacteriocin perspective 
Paula M. O’Connor1,4, R. Paul Ross2,4, Colin Hill3,4 and Paul D. Cotter1,4 
1 Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland 
2 College of Science, Engineering and Food Science, University College Cork, Ireland 
3 School of Microbiology, University College Cork, Ireland 
4 Alimentary Pharmabiotic Centre, Cork, Ireland 
*Corresponding author 
Mailing address: Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork 
E-mail: paul.cotter@teagasc.ie 
Phone: 353 (0)25 42694 
Fax: 353 (0)25 42340 
ABSTRACT 
Efforts are continuing to find novel bacteriocins with enhanced specificity and potency. Traditional 
plating techniques are still being used for bacteriocin screening studies, however, the availability of 
ever more bacterial genome sequences and the use of in silico gene mining tools have revealed 
novel bacteriocin gene clusters that would otherwise have been overlooked. Furthermore, synthetic 
biology and bioengineering-based approaches are allowing scientists to harness existing and novel 
bacteriocin gene clusters through expression in different hosts and by enhancing functionalities. The 
same principles apply to bacteriocin producing probiotic cultures and their application to control 
pathogens in the gut. We can expect that the recent developments on bacteriocins from Lactic Acid 
Bacteria (LAB) described here will contribute greatly to increased commercialisation of bacteriocins 
in food systems. 
INTRODUCTION 
Consumer awareness of the effect of diet on health has led to a demand for minimally processed 
foods in which chemical preservatives are replaced by more natural alternatives. Traditionally foods 
were preserved by (LAB), natural constituents of fermented foods, which confer their preservative 
effects by the production of lactic acid, hydrogen peroxide and small peptides known as 
bacteriocins. Bacteriocins are active against a number of genera (broad spectrum) or particular 
species (narrow spectrum) [1-3] and are very diverse, varying in size, structure and specificity. The 
fact that many bacteriocins are produced by food-grade LAB and possess potent antimicrobial 
activity means that they are ideally suited to controlling food spoilage and pathogenic bacteria [4-6]. 
Bacteriocins can be broadly divided into two classes: class I, of which the lantibiotics (post-
translationally modified peptides containing unusual amino acids) are the best-known example and 
class II, containing unmodified peptides [7]. Their mode of action is likely driven by the primary 
structure of the bacteriocin with membrane permeabilisation being a very common theme. The 
producing culture is protected by the production of specific immunity proteins and the low levels of 
resistance detected so far makes them desirable alternatives to antibiotics. [6]. Their main 
advantage over chemical preservatives is their ability to preserve without affecting the sensory 
qualities of the food while adhering to the demand for natural preservatives. The ideal bacteriocin 
should be potent at low concentrations, active against a range of spoilage and pathogenic 
organisms, innocuous to the host and economical to produce [8]. These antimicrobials can be 
introduced into a food through incorporation of the bacteriocin-producing strain into the food 
product (most commonly in fermented foods), the generation and use of a bacteriocin-containing 
fermentate or as a more concentrated bacteriocin-containing food preservative. Currently only two 
bacteriocins are being used commercially as food preservatives: nisin produced by Lactococcus 
lactis, (marketed as Nisaplin and under other brand names), has been used commercially for 50 
years [9] and carnocyclin A (marketed as Micocin) a circular bacteriocin produced by Carnobacterium 
maltaromaticum UAL307 is an approved biopreservative in the US and Canada developed to inhibit 
Listeria monocytogenes in ready-to-eat meat (RTE) products [10]. This review focuses predominantly 
on bacteriocins as antimicrobial antagonists and efforts to develop them as viable food 
biopreservatives. (See Figure 1) 
THE CONTINUING SEARCH FOR NOVEL BACTERIOCINS 
A primary focus of bacteriocin research is identifying novel bacteriocins and bacteriocin-producing 
strains for specific applications. The general consensus is that the bacteriocin/bacteriocin-producer 
that is best suited to controlling a problematic spoilage/pathogenic microorganism will often be one 
that is found in the same environmental niche. This is based on the expectation that bacteriocins 
provide an advantage to competitors fighting for scarce resources in a particular environment. A 
prime example relates to Weissella hellenica QU 13, isolated from a barrel in which Japanese pickles 
are fermented, which was found to produce two leaderless bacteriocins, weissellicin V, homologous 
to the class IId Enterocin L50A and L50B, and weisselicin M. In the latter case, it is notable that this 
novel broad spectrum class IId antimicrobial is effective against Bacillus coagulans, a known 
contaminant of pickle fermentations. Thus, strain QU 13 is a good example of a fermentation- 
associated isolate which has the potential to be employed to control an undesirable microbial 
contaminant [11]. Lactococcus garvieae is a pathogen affecting farmed and fresh fish from marine 
and freshwaters and is also considered an emerging zoonotic pathogen. Garvicin A, a novel class IIb 
bacteriocin produced by the human isolate L. garvieae 21881, inhibits other L. garvieae stains and 
has potential to treat or prevent L. garvieae infections. More specifically, it is suggested that the 
purified bacteriocin in combination with probiotic LAB would be useful in the fight against L. 
garvieae infections [12]. Another L. garvieae strain, a fermented pork sausage isolate L. garvieae BCC 
43578, produces garvieacin Q, a novel class IId bacteriocin active against other L. garvieae and L. 
monocyto genes [13]. The ability to control L. monocyto genes is a particularly highly sought-after trait 
and it is thus notable that enterocin W, a two component lantibiotic produced by Enterococcus 
faecalis NKR-4-1 isolated from pla-ra Thai fermented fish [14], exhibits activity against this pathogen. 
Given that Staphylococcus aureus is also a major concern for the food industry, it is interesting that 
bactofencin A, a cationic disulphide bond-containing bacteriocin similar to eukaryotic defensins, is 
active against S. aureus. In addition to the unusual nature of this bacteriocin, it is notable that its 
producer, the porcine isolate Lactobacillus salivarius DPC6502, does not contain a classical 
immunity-like gene, but instead encodes a dltB homologue that confers resistance [15]. While the 
examples provided above relate to strains that produce a single bacteriocin, it should be noted that 
the production of multiple bacteriocins by a single strain can be advantageous as the various 
bacteriocins are likely to have different modes of action, thereby extending the spectrum of 
inhibition and reducing the likelihood of development of resistance. The genome of Enterococcus 
faecium NKR-5-3, isolated from pla-ra Thai fermented fish, encodes 5 enterocins, NKR-5-3 –A, B, C, D 
and Z and produces at least four of them, that is NKR-5-3 –A, B, C and D. Enterocin NKR-5-3C was 
confirmed to be a class IIa bacteriocin which exhibits potent antilisterial activity. The other 
bacteriocins are proposed to represent different classes but further investigations are required to 
establish this definitively [16,17]. 
THE PARTICULAR EXPANSION IN NUMBERS OF CIRCULAR BACTERIOCINS 
Although previously regarded as being rare, the discovery of circular bacteriocins has become more 
common in recent years. This is notable as these bacteriocins are thought by some to have the 
potential to form the next generation of biopreservatives as a consequence of their stability and 
activity. Indeed, gassericin A, garvicin ML, lactocyclin Q and leucocyclin Q produced by LAB inhibit a 
range of Gram-positive bacteria including food spoilage bacteria and food pathogens [18]. The 
remarkable stability and activity of these bacteriocins is attributed to their head to tail cyclisation 
which confers the bacteriocins with increased protease and heat resistance [19,20]. Garvicin ML is a 
recently discovered circular bacteriocin produced by L. garvieae DCC43 isolated from a Mallard duck 
which inhibits L. garvieae [21]. Leucocyclin Q, produced by a Japanese pickle isolate Leuconostoc 
mesenteroides TK41401, is particularly active against B. coagulans which, as noted above, is a major 
pickle food spoilage organism [22]. Studies relating to the mode of action of these, and indeed other, 
bacteriocins continue to also attract attention. Notably, in this regard, Liu et al [23] recently noted 
that sublethal doses of carnocyclin A induced an adaptation response in L. monocytogenes 08-5923 
by affecting genes responsible for cell wall biosynthesis and metabolic function maintenance. 
NEW STUDIES RELATING TO THE USE OF BACTERIOCINS AS PART OF A HURDLE APPROACH TO 
PRESERVATION 
Bacteriocins can become more effective biopreservatives when used in combination with other 
antimicrobial hurdles such as organic acids, chelating agents or essential oils. These additive or 
synergistic phenomena act by reducing the levels of bacteriocin required for target inhibition and, in 
some instances, can even extend the spectrum of inhibition of bacteriocins to include Gram-negative 
microorganisms [2]. Cronobacter sakazakii DPC6445 is an opportunistic Gram-negative pathogen 
associated with powdered infant milk formula (PIF) which has been associated with meningitis, 
septicaemia and necrotizing enterocolitis in premature and immunocompromised babies. Producing 
PIF that could be reconstituted at 40-50°C without risk of C. sakazakii infection is of interest to the 
food industry. Significantly, it has recently been established that nisin or lacticin 3147 when 
combined with the lactoperoxidase system inhibited C. sakazakii outgrowth for 8 hours, thereby 
providing an excellent example of a combinatory approach to improving the safety of PIF [24]. 
It has also been frequently demonstrated that using bacteriocins in combination with chelators such 
as ethylenediaminetetraacetic acid (EDTA) can expand the antimicrobial spectrum of a bacteriocin. 
Indeed, although carnocyclin A is not effective against Escherichia coli, Pseudomonas aeroginosa or 
Salmonella Typhimurium when tested alone, it can inhibit E. coli and P. aeruginosa when combined 
with 40 mM EDTA. Anti-E. coli and S. Typhimurium activity could be improved even further when 
nisin, rather than carnocyclin A, was combined with 40 mM EDTA [10]. 
Bacteriocins can also be utilised by applying them to a food surface. Due to lower concentrations 
being sufficient for efficacy in these circumstances, production costs are reduced. The use of 
immobilised bacteriocins, such as nisin, as components of antimicrobial packaging has been the 
focus of increasing levels of research, though it is important to appreciate that understanding the 
mode of action of specific bacteriocins is important to ensuring further progress in the area. In one 
instance nisin was absorbed on both hydrophobic and hydrophilic food films and the effectiveness of 
the active surface against L. monocytogenes, Bacillus cereus and S. aureus was compared. It was 
established that the hydrophilic surfaces were more bioactive and absorbed higher quantities of 
nisin than the hydrophobic surfaces and that S. aureus was most sensitive to the nisin functionalised 
films [25]. Class IIb lactocin 705 and the pediocin like class IIa lactocin CL705 also possess potential in 
this regard. These Lactobacillus curvatus CRL705-produced bacteriocins are active against spoilage 
LAB and Listeria and have been incorporated into wheat gluten films to assess their ability to inhibit 
L. monocyto genes in meat products. The bacteriocin-containing gluten film, made at pilot scale, 
retained antimicrobial activity for 50 days which, importantly, is the shelf life of RTE meat products 
such as cooked sausages [26]. More specifically, the film reduced L. monocyto genes levels in Wiener 
sausages at day 45 by 2.5 log cycles relative to controls [27]. In addition to food surfaces, the 
surfaces of equipment can also serve as a site for the contamination of food by food spoilers and 
pathogens such as L. monocytogenes. Many such bacteria can colonise surfaces such as stainless 
steel and form biofilms. Biocides are routinely used to clean processing equipment but biofilms can 
be particularly difficult to remove. It has recently been established that combining sub-inhibitory 
concentrations of the class IIc enterocin AS-48 with concentrations of biocides 4-10 fold lower than 
their MICs inhibited the growth of planktonic (non-biofilm) L. monocyto genes. Unsurprisingly, higher 
concentrations of both bacteriocin and biocide were required to inhibit sessile cells though synergy 
was still observed [28]. Proteomic analysis of the exposure of L. monocyto genes to enterocin AS-48 
revealed that planktonic and sessile cells respond differently upon exposure to the bacteriocin. 
Planktonic cells may compensate for changes in cytoplasmic permeability by reinforcing 
carbohydrate transport and metabolism while sessile cells shift carbohydrate metabolism and 
reinforce protein synthesis. Both cells states also exhibit a differing response to stress [29]. 
BACTERIOCIN ENGINEERING 
Bacteriocins are ribosomally encoded and therefore are amenable to genetic manipulation through 
engineering, which is defined as modifying the amino acid sequence of a protein to change its 
structure and function [30]. Bioengineering (engineering inside the cell) and the use of synthetic 
biology-based (in vitro engineering) approaches have contributed significantly to our understanding 
of the roles specific amino acids play in structure and activity and resulted in the production of 
bacteriocins which have extended bioactivity against selected pathogens [31]. The structure-activity 
relationship of nisin has been extensively studied through bioengineering and this has enabled 
researchers to design variants with enhanced activity against specific targets. Nisin  S29G, with 
enhanced activity against S. aureus SA113, was found by screening a bank of nisin A variants 
following site directed mutagenesis specifically targeted against this residue. This resulted in the 
generation of a number of variants with improved activity against both Gram-positive and Gram- 
negative pathogens. Indeed, this is the first instance upon which bioengineering of a bacteriocin has 
led to enhanced activity of this kind [32]. Saturation mutagenesis at another location in nisin, lysine 
12, resulted in the finding that a K12A derivative displays increased specific activity against food 
pathogens such as B. cereus, S. aureus and S. agalactieae but not against L. monocytogenes [33]. 
Another region of the nisin peptide, the three amino acid ‘hinge’ region, is particularly amenable to 
change and bioengineering of this region has had beneficial consequences [34]. Indeed, Rouse et al. 
[35] created a bank of hinge mutants and found that nisin peptides containing hinges consisting of 
SVA or NAK (rather than the original NMK) displayed an enhanced ability to diffuse through complex 
polymers, a trait which enabled the variants to outcompete nisin A controlling L. monocyto genes in 
commercially produced chocolate milk containing the stabiliser carrageenan. Furthermore, Healy et 
al. [36] used site directed mutagenesis of the hinge region to create a novel bank of nisin derivatives 
and found that AAK, NAI and SLS had enhanced activity towards some microorganisms. On the basis 
of the observation that the incorporation of small, chiral amino acids at this location generally has 
positive consequences, AAA-containing and SAA-containing ‘hinge’ derivatives were designed, 
created and ultimately became the first example of enhanced nisin derivatives to be generated 
through rational design. 
In the case of another lantibiotic, actagardine A, saturation mutagenesis was employed to engineer 
each amino acid, with the exception of those involved in bridge formation, in turn through using 
saturation mutagenesis. Through this approach it was established that the V15F variant 
demonstrates enhanced activity against Clostridium difficile, E. faecium and E. faecalis [37]. The 
ribosomal nature of bacteriocins also allows for more dramatic changes. To highlight this point, the 
anti-Gram-negative microcin V was combined, through asymmetrical PCR, with the anti -Gram-
positive enterocin 35 to generate the chimeric bacteriocin Ent35-MccV which is active against both 
Gram-positive and Gram-negative pathogens and thus could be of value to the food or 
pharmaceutical industries [38]. Finally, it is now possible to bioengineer circular peptides by 
introducing a covalent bond between the N and C termini using advances in molecular biology and 
protein engineering techniques [30]. Theoretically these techniques could allow the generation of 
more stable bacteriocins with extended applications that could be employed by the food industry. 
Synthetic biology, considered complementary to bioengineering, is another promising area that 
provides insights into structure-stability relationships and the mechanism of action of bacteriocins 
[39,40]. In one instance, Solid Phase Peptide Synthesis (SPPS) has been used to synthesise, and 
modify, lantibiotics such as lacticin 481. Using this approach, the role o f lanthionine and 
methyllanthionine residues was investigated by replacing them with diastereoisomers. In this case it 
was established that activity was lost, suggesting that the 3D structures were modified [41]. 
Synthetic biology also inspired Kong et al [42] to clone the nisin biosynthesis pathway from 
Lactococcus lactis K9 into a plasmid and express it in a nisin deficient strain. They also overexpressed 
nisin A using constitutive promoters and further optimised yield by integrating the structural peptide 
determinant nisA, overexpression cassettes and the recombinant pathway into a single circuit 
enabling the strain to produce 6 fold higher levels of nisin. This could potentially reduce the cost of 
nisin production for the food industry and also provides a means via which novel bacteriocin clusters 
identified through genome mining (see below) could be harnessed. Further efforts to increase 
bacteriocin yield have led to the use of synthetic genes encoding bacteriocins being cloned into and 
expressed in yeasts. A synthetic gene designed using adapted codon usage from the amino acid 
sequence of enterocin A from E. faecium T136 was cloned into Pichia pastoris X-33EAS and 
production levels increased 21.4 fold and antimicrobial activity against a number of listeria strains 
increased 4-603 fold when compared to the natural producer [43]. 
GENOME MINING 
In the past bacteriocin-producing strains have been identified primarily on the basis of culture-based 
approaches. However, traditional plating techniques will reveal bacteriocin producing cultures only if 
the culture produces the bacteriocin under the conditions used for laboratory growth and only if it is 
effective against the target organism chosen for the overlay. Recently there has been a move to 
supplement traditional mining techniques with exploring the genomes of microorganisms from 
under-exploited environments which could be a reservoir of novel bacteriocins. The number of 
genome sequences being deposited in public databases is continually increasing as a consequence of 
significant developments in next generation sequencing technologies. This information is often 
freely available through online databases and provides an opportunity for screening a wide number 
of microorganisms to identify those which have the potential to produce bacteriocins [44,45]. This is 
seen as the dawn of a new era in which in silico and bioengineering based approaches can 
complement, and potentially supersede, culture based methods [45]. Despite this potential, finding 
bacteriocin genomes can be a challenge due to the small size of the structural peptides and diversity 
of their operons. BAGEL 3 is a fast genome mining tool that can identify putative bacteriocins based 
on conserved domains in structural, biosynthetic, transport and immunity genes [46]. In addition the 
BACTIBASE database is a manually curated repository of bacteriocin sequences that can also be 
helpful. [47]. Mass spectrometry is also being used more often in the quest for novel bacteriocins. 
Natural Product Peptidogenomics is a mass spectrometry based genome mining approach that 
connects chemotypes with biosynthetic gene clusters, the objective being to match a series of mass 
shifts from MSn spectrum of a putative bacteriocin to the genes responsible for production [48].  
Zendo and co-workers [49,50] developed a rapid screening method using electrospray ionisation 
liquid chromatography/mass spectrometry (ESI/LC/MS) coupled with statistical analysis of 
antimicrobial spectra to accelerate the discovery of novel bacteriocins isolated from various sources. 
An example of a novel lantibiotic that has recently been discovered using a genome mining and PCR 
approach is the broad spectrum cerecidin A1 and cerecidin A7 from B. cereus strain As 1.1846 
isolated from spoiled soya milk. The cer locus differs from other class II lantibiotics in that it contains 
seven tandem precursor cerA genes and the cerecidins are notably active against multidrug resistant 
S. aureus (MDRSA) and vancomycin resistant E. faecalis (VRE) [51]. 
PROBIOTICS 
Finally, over the last few years there has been growing evidence that bacteriocin production confers 
a number of advantages on probiotic strains. It is proposed that the ability to produce bacteriocins 
may help a strain to establish itself in a new niche, inhibit competitors and pathogens, alter the 
composition of the microbiota and even modulate the host immune system [52]. A recent study of 
the gut microbiota of elderly Irish subjects revealed Enterococcus strains with anti-listerial activity, 
which merit closer attention with a view to investigating their use as probiotic strains. In addition, a 
Lactobacillus gasseri strain producing gassericin T was isolated during the same screening 
programme [53]. Notably, Lb. gasseri bacteriocins are very active against Gram-positive pathogens 
and have potential as food preservatives due to their heat stability and pH stability. Lb. gasseri have 
been evaluated as probiotics and these investigations have also highlighted its tolerance of low pH 
environments, resistance to bile salts, ability to adhere to the host epithelium modulate the innate 
and adaptive immune system [54]. There have also been a number of recent studies that have 
highlighted the impact of the Abp118 bacteriocin by Lactobacillus salivarius UCC118 on the overall 
composition of the gut microbiota and on the host epithelium [55-57]. Finally, a study of LAB 
associated with fish for human consumption showed that bacteriocin activity against fish pathogens 
is a widespread probiotic property. Indeed LAB active against lactococcosis were common among 
LAB isolated from edible fish, further supporting the theory that the best place to find antimicrobials 
against a specific pathogen is in the niche the pathogen proliferates [58]. 
CONCLUSION 
In conclusion, there is a continued drive to find novel bacteriocins that can control food pathogens 
more effectively. Novel LAB bacteriocins continue to be discovered and the use of LAB that produce 
multiple bacteriocins is receiving renewed attention. These screening programmes are being aided 
by the use of genome mining and mass spectrometry to find and characterise new bacteriocins while 
new engineering based approaches are being used in parallel to improve previously identified 
bacteriocins for particular applications /targets. There is great potential to carry out investigations 
that would assess the impact of bacteriocins on an entire food microbial consortia as has been done 
previously to assess the impact of bacteriocins on gut microbial populations [56, 59]. 
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